SYRE - Spyre Therapeutics, Inc.
IEX Last Trade
23.615
-0.175 -0.741%
Share volume: 2,698
Last Updated: Fri 27 Dec 2024 04:30:36 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.12%
PREVIOUS CLOSE
CHG
CHG%
$23.79
-0.18
-0.74%
Fundamental analysis
35%
Profitability
50%
Dept financing
14%
Liquidity
75%
Performance
16%
Performance
5 Days
-1.06%
1 Month
-16.13%
3 Months
-19.68%
6 Months
-0.21%
1 Year
20.93%
2 Year
60.97%
Key data
Stock price
$23.62
DAY RANGE
$23.79 - $24.32
52 WEEK RANGE
$21.19 - $47.97
52 WEEK CHANGE
$13.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jeffrey M. Goldberg
Region: US
Website: aeglea.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aeglea.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aeglea BioTherapeutics, Inc. designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pezilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial. It also develops AGLE-177, a polyethylene glycol modified, which is in clinical trials for homocystinuria.
Recent news